Skip to content

Study · Animal study (in vivo) · rat · 2023

13 results

The Mitochondrial-Derived Peptide (MOTS-c) Interacted with Nrf2 to Defend the Antioxidant System to Protect Dopaminergic Neurons Against Rotenone Exposure.

Xiao J, Zhang Q, Shan Y, Ye F, Zhang X, Cheng J, Wang X, Zhao Y, Dan G, Chen M, Sai Y

Molecular neurobiology28 Jun 2023Cited by 17 (Europe PMC)

PMID37380822 (opens in a new tab)DOI10.1007/s12035-023-03443-3 (opens in a new tab)PepBankPUB-37380822
Publisher pagePubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to rotenone, exogenous MOTS‑c pretreatment protected against mitochondrial dysfunction.

    In plain wordsIn rats given rotenone, MOTS‑c given before rotenone protected against damage to energy-producing parts of cells.

    Peptide
    MOTS-c
    Outcome
    DecreaseMitochondrial dysfunction in rats
    Study

    ratn: not reported in source

    Rotenone-exposed rats
    Comparator
    Rotenone without MOTS-c pretreatment
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vivo and in vitro experiments demonstrated that exogenous MOTS-c pretreatment could protect PC12 cells and rats from mitochondrial dysfunction and oxidative stress induced by rotenone.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to rotenone, exogenous MOTS‑c pretreatment protected against oxidative stress.

    In plain wordsIn rats given rotenone, MOTS‑c given before rotenone protected against oxidative stress.

    Peptide
    MOTS-c
    Outcome
    DecreaseOxidative stress in rats
    Study

    ratn: not reported in source

    Rotenone-exposed rats
    Comparator
    Rotenone without MOTS-c pretreatment
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vivo and in vitro experiments demonstrated that exogenous MOTS-c pretreatment could protect PC12 cells and rats from mitochondrial dysfunction and oxidative stress induced by rotenone.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to rotenone, MOTS‑c pretreatment significantly decreased the loss of TH protein expression in the striatum.

    In plain wordsIn rats given rotenone, MOTS‑c given before rotenone reduced the loss of TH protein in the brain's striatum.

    Peptide
    MOTS-c
    Outcome
    IncreaseStriatal TH protein expression
    Study

    ratn: not reported in source

    Rotenone-exposed rats (striatum)
    Comparator
    Rotenone without MOTS-c pretreatment
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, MOTS-c pretreatment significantly decreased the loss of TH, PSD95, and SYP protein expression in the striatum of rats exposed to rotenone.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to rotenone, MOTS‑c pretreatment significantly decreased the loss of PSD95 protein expression in the striatum.

    In plain wordsIn rats given rotenone, MOTS‑c given before rotenone reduced the loss of PSD95 protein in the brain's striatum.

    Peptide
    MOTS-c
    Outcome
    IncreaseStriatal PSD95 protein expression
    Study

    ratn: not reported in source

    Rotenone-exposed rats (striatum)
    Comparator
    Rotenone without MOTS-c pretreatment
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, MOTS-c pretreatment significantly decreased the loss of TH, PSD95, and SYP protein expression in the striatum of rats exposed to rotenone.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats exposed to rotenone, MOTS‑c pretreatment significantly decreased the loss of SYP protein expression in the striatum.

    In plain wordsIn rats given rotenone, MOTS‑c given before rotenone reduced the loss of SYP protein in the brain's striatum.

    Peptide
    MOTS-c
    Outcome
    IncreaseStriatal SYP protein expression
    Study

    ratn: not reported in source

    Rotenone-exposed rats (striatum)
    Comparator
    Rotenone without MOTS-c pretreatment
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, MOTS-c pretreatment significantly decreased the loss of TH, PSD95, and SYP protein expression in the striatum of rats exposed to rotenone.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In rats exposed to rotenone, MOTS‑c pretreatment alleviated the downregulated Nrf2 expression in the striatum.

    In plain wordsIn rats given rotenone, MOTS‑c given before rotenone reduced the drop in Nrf2 in the brain's striatum.

    Peptide
    MOTS-c
    Outcome
    IncreaseStriatal Nrf2 expression
    Study

    ratn: not reported in source

    Rotenone-exposed rats (striatum)
    Comparator
    Rotenone without MOTS-c pretreatment
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MOTS-c pretreatment could clearly alleviate the downregulated expression of Nrf2, HO-1, and NQO1, as well as the upregulated Keap1 protein expression in the striatum of rotenone-treated rats.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In rats exposed to rotenone, MOTS‑c pretreatment alleviated the downregulated HO-1 expression in the striatum.

    In plain wordsIn rats given rotenone, MOTS‑c given before rotenone reduced the drop in HO-1 in the brain's striatum.

    Peptide
    MOTS-c
    Outcome
    IncreaseStriatal HO-1 expression
    Study

    ratn: not reported in source

    Rotenone-exposed rats (striatum)
    Comparator
    Rotenone without MOTS-c pretreatment
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MOTS-c pretreatment could clearly alleviate the downregulated expression of Nrf2, HO-1, and NQO1, as well as the upregulated Keap1 protein expression in the striatum of rotenone-treated rats.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In rats exposed to rotenone, MOTS‑c pretreatment alleviated the downregulated NQO1 expression in the striatum.

    In plain wordsIn rats given rotenone, MOTS‑c given before rotenone reduced the drop in NQO1 in the brain's striatum.

    Peptide
    MOTS-c
    Outcome
    IncreaseStriatal NQO1 expression
    Study

    ratn: not reported in source

    Rotenone-exposed rats (striatum)
    Comparator
    Rotenone without MOTS-c pretreatment
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MOTS-c pretreatment could clearly alleviate the downregulated expression of Nrf2, HO-1, and NQO1, as well as the upregulated Keap1 protein expression in the striatum of rotenone-treated rats.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In rats exposed to rotenone, MOTS‑c pretreatment alleviated the upregulated Keap1 protein expression in the striatum.

    In plain wordsIn rats given rotenone, MOTS‑c given before rotenone reduced the rise in Keap1 protein in the brain's striatum.

    Peptide
    MOTS-c
    Outcome
    DecreaseStriatal Keap1 protein expression
    Study

    ratn: not reported in source

    Rotenone-exposed rats (striatum)
    Comparator
    Rotenone without MOTS-c pretreatment
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    as well as the upregulated Keap1 protein expression in the striatum of rotenone-treated rats.
  10. 10LabIn vitro (cells)Efficacy outcome

    In PC12 cells, exogenous MOTS‑c pretreatment protected against rotenone-induced mitochondrial dysfunction.

    In plain wordsIn cells, MOTS‑c given before rotenone protected against damage to the cells' energy-producing parts.

    Peptide
    MOTS-c
    Outcome
    DecreaseMitochondrial dysfunction in PC12 cells
    Study

    n: not reported in source

    PC12 cells exposed to rotenone
    Comparator
    Rotenone without MOTS-c pretreatment
    Outcome group
    Mitochondrial function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vivo and in vitro experiments demonstrated that exogenous MOTS-c pretreatment could protect PC12 cells and rats from mitochondrial dysfunction and oxidative stress induced by rotenone.
  11. 11LabIn vitro (cells)Efficacy outcome

    In PC12 cells, exogenous MOTS‑c pretreatment protected against rotenone-induced oxidative stress.

    In plain wordsIn cells, MOTS‑c given before rotenone protected against oxidative stress.

    Peptide
    MOTS-c
    Outcome
    DecreaseOxidative stress in PC12 cells
    Study

    n: not reported in source

    PC12 cells exposed to rotenone
    Comparator
    Rotenone without MOTS-c pretreatment
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vivo and in vitro experiments demonstrated that exogenous MOTS-c pretreatment could protect PC12 cells and rats from mitochondrial dysfunction and oxidative stress induced by rotenone.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 12LabEndogenous levelIn vitro (cells)Mechanism

    In PC12 cells, rotenone significantly changed the expression and localization of the cells' own MOTS‑c, with more MOTS‑c moving from mitochondria into the nucleus.

    In plain wordsIn cells, rotenone changed where the cells' own MOTS‑c sits, moving more of it into the nucleus.

    Peptide
    MOTS-c
    Outcome
    IncreaseMOTS-c nuclear translocation under rotenone
    Study

    n: not reported in source

    PC12 cells exposed to rotenone
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    In an in vitro study, it was observed that rotenone could influence the expression and localization of MOTS-c significantly in PC12 cells, with more MOTS-c translocating into the nucleus from mitochondria.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

  2. 13LabEndogenous levelIn vitro (cells)Mechanism

    In PC12 cells exposed to rotenone, MOTS‑c moving from mitochondria into the nucleus directly interacted with Nrf2 to regulate HO-1 and NQO1 expression.

    In plain wordsIn cells exposed to rotenone, the cells' own MOTS‑c moved into the nucleus and bound Nrf2, which controls HO-1 and NQO1.

    Peptide
    MOTS-c
    Outcome
    Not applicableMOTS-c interaction with Nrf2 and HO-1 and NQO1 expression
    Study

    n: not reported in source

    PC12 cells exposed to rotenone
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Further study showed that the translocation of MOTS-c from the mitochondria into the nucleus could directly interact with Nrf2 to regulate HO-1 and NQO1 expression in PC12 cells exposed to rotenone, which had been suggested to be involved in the antioxidant defense system.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.